While Corcept Therapeutics Inc has overperformed by 2.66%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CORT rose by 7.76%, with highs and lows ranging from $117.33 to $32.99, whereas the simple moving average fell by -48.83% in the last 200 days.
On December 31, 2025, Wolfe Research Downgraded Corcept Therapeutics Inc (NASDAQ: CORT) to Underperform. A report published by UBS on December 16, 2025, Initiated its previous ‘Neutral’ rating for CORT. Truist November 06, 2023d the rating to Buy on November 06, 2023, and set its price target from $29 to $38. SVB Securities initiated its ‘Market Perform’ rating for CORT, as published in its report on April 11, 2023. Piper Sandler’s report from April 04, 2023 suggests a price prediction of $27 for CORT shares, giving the stock a ‘Overweight’ rating. Jefferies also rated the stock as ‘Hold’.
Analysis of Corcept Therapeutics Inc (CORT)
Further, the quarter-over-quarter increase in sales is 13.75%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Corcept Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 16.47% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.07, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CORT is recording an average volume of 1.45M. On a monthly basis, the volatility of the stock is set at 6.00%, whereas on a weekly basis, it is put at 6.15%, with a loss of -1.83% over the past seven days. Furthermore, long-term investors anticipate a median target price of $91.00, showing growth from the present price of $37.5, which can serve as yet another indication of whether CORT is worth investing in or should be passed over.
How Do You Analyze Corcept Therapeutics Inc Shares?
A leading company in the Biotechnology sector, Corcept Therapeutics Inc (CORT) is based in the USA. When comparing Corcept Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 42.85, there is a growth in quarterly earnings of -60.52%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.68%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 74.67% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
